Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GBT Technologies to release the first version of its AI-powered human vitals device, qTerm with only three of the four originally-planned features included. He explained that this was a decision made to meet the demand brought on by the COVID-19 pandemic.$GTCH
GBT Technologies Inc is engaged in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies, including wireless mesh network technology platform and fixed solutions, development of an intelligent human body vitals device, prepaid services, asset-tracking IoT, and wireless mesh networks.$GTCH
Lodonal™ is Immune Therapeutics, Inc.’s approved immune modulator for use in emerging nations. Lodonal™, based on the Low Dose Naltrexone formulation, IRT-103/Lodonal™ currently in use with Immune’s wholly owned subsidiary Cytocom, Inc. is designed to offer affordable immune modulation in countries exhibiting the most need for improved health with low cost while developing their own advanced health care systems. Currently, Lodonal™ has received approval in Nigeria following a successful bridging trial.$IMUN
Immune Therapeutic's platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF.$IMUN
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs $IMUN
Immune Therapeutics Inc. (OTC PINK: IMUN), a clinical-stage pharmaceutical company, and Forte Biotechnology Intl Corp, a privately-held biotech company focused on innovations in the veterinary drug space, today announced their entry into a licensing agreement whereby Immune Therapeutics sub-licensed so Forte Biotechnology exclusive worldwide rights to research, develop and commercialize Lodonal (IRT=103) and IRT-101 for the for the treatment of immune disfunction, inflammatory diseases and cancer in companion animals.$IMUN
Immune Therapeutics Inc is a specialty pharmaceutical company operating in the USA. It engages in the commercialization of patented therapies focused on the activation and re-balancing of the body's immune system. The company is involved in acquiring the patent for the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (LDN) and Methionine [Met5]-enkephalin (MENK).$IMUN
Immune Therapeutics benefits patients with chronic diseases by rebalancing their bodies' immune system by using a patented immunotherapy.$IMUN
Immune holds a major equity stake of their successful Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) in relation to the Cytocom’s planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2, the virus responsible for COVID-19. Based on the FDA’s feedback, Cytocom plans to revise the study protocol and quickly initiate enrollment.$IMUN
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial.$IMUN
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial.$IMUN
Lodonal™ is Immune Therapeutics, Inc.’s approved immune modulator for use in emerging nations. Lodonal™, based on the Low Dose Naltrexone formulation, IRT-103/Lodonal™ currently in use with Immune’s wholly owned subsidiary Cytocom, Inc.$IMUN
Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life-threatening diseases by stimulating or rebalancing the immune system.$IMUN
Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has launched 7 new dietary supplements in addition to its original product, Essential 9TM.$SBFM
Sunshine Biopharma, Inc. is a pharmaceutical company. It is engaged in the the research, development and commercialization of drugs for the treatment of various forms of cancer. The firm's products include Adva-27a, SBI-Anastrozol, SBI-Letrozole, SBI-Bicalutamide, SBI-Finasteride, and Essential 9.$SBFM
Sunshine Biopharma’s Essential 9™ provides all 9 Essential Amino Acids in ready for absorption, free-form and in the proportions recommended by Health Canada.
Essential 9™ contains the exact constituents of the scientifically proven set of essential amino acids. Essential 9™ is suitable for everyone: vegans, athletes, seniors, dieters and anyone wishing to increase their health!$SBFM
Sunshine Biopharma is committed to developing novel therapies for the treatment of various forms of aggressive cancer types.$SBFM
On May 22, 2020 , Sunshine Biopharma filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness.$SBFM
The 2020 Bio/Pharma Virtual Congress event will connect bio/pharma formulation, development, manufacturing, and quality experts with a full day of technical presentations, panel discussions, interviews, and vendor meetings, through an interactive portal.
This online event will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry.$SBFM
Good Morning
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug.$SBFM
Sunshine Biopharma is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date.$SBFM
n addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.$SBFM
Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has screened and subsequently identified a lead compound from its library of Coronavirus protease inhibitors.$SBFM
Holiday Island Holdings, Inc. (OTCPink: HIHI) is a development stage company involved with recreational, residential, and commercial real estate in our defined regional market.$HIHI
"Following an extensive evaluation and diligence process, the Immune Board of Directors concluded that the acquisition of Aletheia, with a strong platform technology, seasoned leadership team, and compelling clinical development plan.$IMUN
mmune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company$IMUN
mmune Therapeutics, Inc. operates as a biotechnology company. The Company focuses on research new treatments and methods for treatment of cancer, HIV/AIDS, and certain other autoimmune and infectious diseases.$IMUN
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs $IMUN
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial. $IMUN
Lodonal™ is Immune Therapeutics, Inc.’s approved immune modulator for use in emerging nations.$IMUN
GTCH's technology is targeted for integration into a wide variety of leading applications, among them are autonomous machines, smart drones, military and rescue, law enforcement, GEO tracking, medicine, robotics and more.$GTCH
TY resx18 !
GTCH products are connected to our private, secured communication protocol and enable our technology to control and manage more data from more places. This will ensure greater efficiency of digital and inter-personal communications, thus improving our lives and security.$GTCH
GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), announced that it received a notice of allowance for application number 16/292,388, which was filed on March 5, 2019, issued by the United States Patent and Trademark Office (“USPTO”) for its 3D, Monolithic, multi-dimensional, multi-plane, memory structure for integrated circuits patent. The application has been examined by USPTO and is allowed for issuance as a patent. The Company expects that it will receive a granted date during the next few months.$GTCH
GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), announced that it received a notice of allowance for application number 16/292,388, which was filed on March 5, 2019, issued by the United States Patent and Trademark Office (“USPTO”) for its 3D, Monolithic, multi-dimensional, multi-plane, memory structure for integrated circuits patent. The application has been examined by USPTO and is allowed for issuance as a patent. The Company expects that it will receive a granted date during the next few months.$GTCH
PCTL is happy to welcome BOX Bioscience into our growing distributor family. Their knowledge of this market space coupled with their current business operations give them an advantage. As a level three distributor, BOX joins a select, but growing group within our distributor network.$PCTL
PCTL's large network of distributors and sub-registrants may also count hospital and healthcare facilities among their clientele in different geographical regions. PCTL will be providing additional updates regarding its growing network of distributors and sub-registrants in a release in the near future.$PCTL
Through the company’s primary healthcare distributor, ACE Janitorial Services, PCTL now has 18 hospitals in the US which are using the company’s bottled Hydrolyte® solution or utilizing on-site equipment, primarily PCTL’s Annihilyzer® Infection Control System.$PCTL